Summary
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
Cytosorbents Corporation ( CTSO ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Phillip Chan - CEO & Director Peter Mariani - Chief Financial Officer Conference Call Participants Adanna Alexander Brian Lantier - Zacks Small-Cap Research Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents Corp. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 13 of 2025.
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Peter J. Mariani - Chief Financial Officer Phillip P.
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis Deliargyris - Chief Medical Officer Pete Mariani - Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C. Wainwright Michael Kim - Zacks Small-Capital Research Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents First Quarter 2025 Earnings Conference Call.
Cytosorbents Corporation (CTSO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Cytosorbents Corporation ever had a stock split?
Cytosorbents Corporation Profile
| Biotechnology Industry | Healthcare Sector | Phillip P. Chan CEO | NASDAQ (CM) Exchange | 23283X206 CUSIP |
| US Country | 149 Employees | - Last Dividend | 5 Dec 2014 Last Split | - IPO Date |
Overview
Cytosorbents Corporation is a pioneer in the development and commercialization of cutting-edge medical devices centered around its innovative blood purification technology, which leverages a unique adsorbent and porous polymer technology. Established in 1997 and initially known as MedaSorb Technologies Corporation until a name change in May 2010, the company is headquartered in Princeton, New Jersey. With a substantial global footprint, Cytosorbents extends its services across the United States, Germany, and other international markets, focusing on addressing critical care applications, sepsis treatment, organ transplant quality enhancement, and more. The firm is committed to improving medical outcomes through its groundbreaking products.
Products and Services
CytoSorb: This flagship extracorporeal cytokine adsorber is designed for use as adjunctive therapy in the management of sepsis, various critical care applications, prevention, and treatment of perioperative complications, and to enhance the quality of organs for transplantation.
VetResQ: A specialized device targeting the veterinary market, VetResQ is utilized as an adjunctive therapy in the treatment of critical conditions such as sepsis and pancreatitis in animals.
CytoSorb-XL: Currently under development, this device aims to offer an improved solution for adjunctive therapy in the treatment of sepsis and other life-threatening conditions.
HemoDefend: This blood purification platform is designed to remove contaminants from blood and blood products, helping to prevent transfusion reactions or diseases transferred through blood transfusions, and it also facilitates the removal of anti-A and anti-B antibodies from whole blood and plasma.
K+ontrol: Specifically developed for the urgent treatment of severe hyperkalemia, K+ontrol seeks to save lives by managing this life-threatening condition effectively.
ContrastSorb: A device in development designed to reduce the risk of contrast-induced nephropathy by removing IV contrast used in CT imaging, angiograms, or vascular interventional radiology procedures from the bloodstream.
BetaSorb: Targeting chronic renal failure, BetaSorb is intended for the prevention and treatment of health complications arising from the accumulation of metabolic toxins.
DrugSorb: This device aims at removing drugs and chemicals from the bloodstream, catering to a wide range of medical applications.
DrugSorb-ATR: An antithrombotic removal system in development, designed to enhance patient care by removing antithrombotic agents from the blood.
Contact Information
